Product image of Moloxin (Moxifloxacin) supplied by GNH India

Moloxin

Active Ingredient:
Moxifloxacin
Origin:
EU

Moloxin (Moxifloxacin)

Moxifloxacin, the active ingredient in Moloxin, is a fluoroquinolone antibiotic presented as an injection for intravenous use. It treats a range of serious bacterial infections in adult patients.

GNH India supplies Moloxin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Moloxin is a fluoroquinolone antibiotic indicated for several serious bacterial infections.
  • Community‑acquired bacterial pneumonia: rapid bacterial eradication leading to clinical cure.
  • Acute bacterial sinusitis: resolution of sinus infection symptoms.
  • Acute exacerbations of chronic bronchitis: reduction of bacterial load and improvement of airflow.
  • Skin and skin structure infections: effective treatment of Gram‑positive and Gram‑negative pathogens.
  • Intra‑abdominal infections: broad‑spectrum coverage for mixed aerobic and anaerobic organisms.

How It Works

  • Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By blocking these targets, the drug prevents bacterial DNA synthesis, leading to rapid bactericidal activity against a wide range of Gram‑positive and Gram‑negative organisms.

Side Effects

Moloxin may cause a variety of adverse reactions. Monitoring and prompt reporting are recommended.

Common Side Effects

  • Nausea
  • Diarrhea
  • Headache
  • Dizziness
  • Rash
  • Transient elevation of liver enzymes

Serious or Rare Side Effects

  • Tendon rupture or tendinitis
  • QT interval prolongation and potential arrhythmias
  • Severe allergic reactions including anaphylaxis
  • Clostridioides difficile‑associated colitis
  • Hepatic failure
  • Stevens‑Johnson syndrome or toxic epidermal necrolysis

Precautions & Warnings

  • When using Moloxin, clinicians should consider several safety measures.
  • Renal impairment: adjust monitoring as drug clearance may be reduced.
  • Hepatic impairment: use with caution due to hepatic metabolism.
  • History of tendon disorders: avoid because of increased risk of tendon rupture.
  • QT prolongation risk: contraindicated in patients with known prolonged QT or on other QT‑prolonging agents.
  • Pregnancy and lactation: safety not established; prescribe only if benefit outweighs risk.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Moloxin can interact with other medicines, requiring careful assessment.

Major Interactions (Avoid)

  • Co‑administration with other fluoroquinolones: additive toxicity.
  • Concurrent use of QT‑prolonging drugs (e.g., macrolides, antiarrhythmics): heightened risk of cardiac arrhythmia.
  • Systemic corticosteroids: increased risk of tendon rupture.
  • Antacids containing aluminum or magnesium (for oral forms): may reduce absorption (relevant for oral equivalents).
  • Strong CYP1A2 inhibitors: may raise moxifloxacin plasma levels.

Moderate Interactions (Monitor Closely)

  • Warfarin: may enhance anticoagulant effect; monitor INR.
  • Theophylline: possible increase in plasma concentration; watch for toxicity.
  • Caffeine and other CYP1A2 substrates: may experience elevated levels; adjust intake as needed.

Frequently Asked Questions

Moloxin is an intravenous formulation of the fluoroquinolone moxifloxacin. It is prescribed for serious bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, exacerbations of chronic bronchitis, skin and soft‑tissue infections, and intra‑abdominal infections.

Moxifloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This inhibition stops bacterial cells from multiplying, leading to rapid bactericidal activity against a broad spectrum of Gram‑positive and Gram‑negative organisms.

The exact dose and infusion rate of Moloxin are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local guidelines. No fixed regimen is provided here.

Safety data for moxifloxacin during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and after careful risk‑benefit assessment by the prescriber.

To order Moloxin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Moloxin (moxifloxacin) offers a broader spectrum against Gram‑positive organisms and enhanced activity against atypical pathogens compared with older fluoroquinolones such as ciprofloxacin. It also has a higher risk of QT prolongation, so cardiac monitoring may be more important than with some alternatives.

Moloxin vials should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to use, inspect the solution for particulate matter and ensure aseptic technique during preparation and administration.

Moloxin is given by intravenous infusion. The prescriber selects the infusion rate and duration, typically over 30‑60 minutes, based on the patient’s clinical status and institutional protocols. Administration should be performed by qualified healthcare personnel in a sterile environment.

Serious risks include tendon rupture or tendinitis, QT interval prolongation leading to arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, hepatic failure, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome.

Moloxin is contraindicated in patients with known hypersensitivity to moxifloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, and individuals with a prolonged QT interval not corrected by therapy. Caution is also advised for patients with severe hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Moxifloxacin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT